These innovative treatments, Semaglutide , represent a groundbreaking advancement in treating metabolic dysfunction and potentially associated ailments . These drugs are categorized as GLP-1 pathway https://adrianadszu768716.ivasdesign.com/62591722/semaglutide-a-deep-examination-into-incretin-agents